“Lori is a valued leader and strategic partner who has been instrumental in building the company’s financial organization,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Lori brings the deep financial and accounting knowledge and operational experience needed to lead the business to sustainable growth as we become a fully commercial organization and help create long-term value for all of our stakeholders.”
As CFO, Ms. Macomber will direct the company’s financial operations and retain her responsibilities as the company’s chief financial officer and accounting officer. Since joining Legend Biotech in September 2019, Ms. Macomber has served as Vice President of Finance and Vice President of Supply Chain Finance and Controller.
Prior to Legend, Ms. Macomber was Business Unit Controller at Ametek PDS, a leading supplier of components and systems to the aerospace and defense industries. In her career as a finance professional, Ms. Macomber has also held various senior finance and accounting positions in the life sciences industry, including US CFO and Controller of Cello Heath and AVP Finance Site Leader at Eli Lilly & Company.
Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Chartered Accountant.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we develop advanced cell therapies on a variety of technology platforms, including autologous and allogeneic chimeric antigen receptor T cells, T cell receptors (TCR-T), and natural killer (NK) cells. based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to advance the discovery of safe, effective, and cutting-edge therapeutics for patients around the world.
Learn more at www.legendbiotech.com and follow us Twitter and LinkedIn.
Statements in this press release regarding future expectations, plans and prospects, and all other statements relating to matters that are not historical facts, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to statements regarding Legend Biotech’s strategies and objectives; statements regarding CARVYKTI™, including Legend Biotech’s expectations for CARVYKTI™, such as Legend Biotech’s expectations regarding the manufacture and commercialization of CARVYKTI™ and the potential effect of treatment with CARVYKTI™; statements regarding filings for Cilta-cel with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Chinese Center for Drug Evaluation of the National Medical Products Administration (CDE) and the progress of such filings by other regulatory agencies; the anticipated timing and ability to advance clinical trials, including patient enrollment; filing Investigational New Drug (IND) applications with regulatory authorities and maintaining such applications with regulatory authorities; the ability to generate, analyze and present clinical trial data; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “should,” “goal,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from those projected in such forward-looking statements as a result of a number of important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or data analysis, or government regulations generally; unexpected delays due to the actions or omissions of our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other protected intellectual property, including uncertainties related to the US litigation; competition in general; government, industry and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; and the other factors discussed in the “Risk Factors” section of Legend Biotech’s annual report filed with the Securities and Exchange Commission on March 31, 2022. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described as anticipated, believed, estimated or anticipated in this press release. All forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005354/en/